SG3185G - Compositions containing 1,3-dimethyl-5-aminoadamantane - Google Patents

Compositions containing 1,3-dimethyl-5-aminoadamantane

Info

Publication number
SG3185G
SG3185G SG31/85A SG3185A SG3185G SG 3185 G SG3185 G SG 3185G SG 31/85 A SG31/85 A SG 31/85A SG 3185 A SG3185 A SG 3185A SG 3185 G SG3185 G SG 3185G
Authority
SG
Singapore
Prior art keywords
aminoadamantane
dimethyl
compositions containing
compositions
Prior art date
Application number
SG31/85A
Other languages
English (en)
Original Assignee
Merz & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Company filed Critical Merz & Company
Publication of SG3185G publication Critical patent/SG3185G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG31/85A 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane SG3185G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856393A DE2856393C2 (de) 1978-12-27 1978-12-27 Arzneimittel zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
SG3185G true SG3185G (en) 1985-06-14

Family

ID=6058522

Family Applications (1)

Application Number Title Priority Date Filing Date
SG31/85A SG3185G (en) 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane

Country Status (10)

Country Link
US (1) US4273774A (fr)
JP (1) JPS5589219A (fr)
BE (1) BE880905A (fr)
CA (1) CA1121726A (fr)
DE (1) DE2856393C2 (fr)
FR (1) FR2445145A1 (fr)
GB (1) GB2044098B (fr)
NL (1) NL7909307A (fr)
SE (1) SE448517B (fr)
SG (1) SG3185G (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33080E (en) * 1981-08-31 1989-10-03 Exxon Research And Engineering Company Adamantane catalyzed paraffin isomerization
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
WO2005000216A2 (fr) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combinaison d'un antagoniste du recepteur nmda et inhibiteur du recaptage de serotonine selectif pour le traitement de la depression et d'autres troubles de l'humeur
JP2006527774A (ja) * 2003-06-16 2006-12-07 アラーガン、インコーポレイテッド メマンチン経口製剤
US20050113458A1 (en) * 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060020042A1 (en) * 2004-01-05 2006-01-26 Forest Laboratories, Inc. Memantine for the treatment of mild and mild to moderate Alzheimer's disease
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
WO2006096194A2 (fr) 2004-06-17 2006-09-14 Merz Pharma Gmbh & Co. Kgaa Formulations a liberation immediate de formes de dosage oral de memantine
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
AU2005286672B2 (en) * 2004-09-23 2009-03-12 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2607600A1 (fr) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Formulation de gouttes de memantine a liberation modifiee et immediate
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2008005534A2 (fr) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
RU2450004C2 (ru) 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
WO2008063847A2 (fr) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Méthode de traitement de l'autisme
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
EP2111858A1 (fr) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
WO2012052451A1 (fr) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate
KR20130132829A (ko) 2010-10-29 2013-12-05 메르츠 파마 게엠베하 운트 코. 카가아 인돌 유도체 및 이의 제조 방법
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
WO2012085166A1 (fr) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs glutamatergiques métabotropes
WO2012085167A1 (fr) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs glutamatergiques métabotropes
WO2012152854A1 (fr) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2938671A1 (fr) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Compositions de donepezil et procede de traitement de la maladie d'alzheimer
EP3310785B1 (fr) 2015-06-19 2024-11-20 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
IL260290B2 (en) 2015-12-30 2023-11-01 Corium Inc Systems and methods for long-term percutaneous administration
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
CN109789134A (zh) 2016-07-27 2019-05-21 考里安国际公司 与口服递送药代动力学生物等效的透皮递送系统
JP7153010B2 (ja) 2016-07-27 2022-10-13 コリウム， インコーポレイテッド 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
CA3086163A1 (fr) 2017-12-20 2019-06-27 Corium, Inc. Composition adhesive transdermique comprenant un agent therapeutique liquide volatil a bas point de fusion
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
CN119095622A (zh) 2022-02-08 2024-12-06 菲克雷特·萨欣 Nmdar拮抗剂通过提高20s蛋白酶体活性来预防老化和老化相关病况和疾病
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864489A (en) * 1972-03-20 1975-02-04 Gen Foods Corp Treatment of hyperkinetic conditions with caffeine
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
DE2518677A1 (de) * 1974-05-06 1975-11-20 Sandoz Ag Neue pharmazeutische zubereitungen

Also Published As

Publication number Publication date
GB2044098B (en) 1983-01-26
JPS5589219A (en) 1980-07-05
GB2044098A (en) 1980-10-15
FR2445145B1 (fr) 1984-10-26
SE7910501L (sv) 1980-06-28
SE448517B (sv) 1987-03-02
US4273774A (en) 1981-06-16
NL7909307A (nl) 1980-07-01
DE2856393A1 (de) 1980-07-03
FR2445145A1 (fr) 1980-07-25
CA1121726A (fr) 1982-04-13
DE2856393C2 (de) 1983-04-28
BE880905A (fr) 1980-06-27

Similar Documents

Publication Publication Date Title
SG3185G (en) Compositions containing 1,3-dimethyl-5-aminoadamantane
JPS54139654A (en) Composition
GB2011917B (en) Rubber compositions containing 1,2-polybutadience
IL60491A0 (en) 2,2-difluoro-6a-carba-pgi2 compounds
IL57923A (en) 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones
ZA796336B (en) 1,2,4,5-tetra-alkyl-4-arylpiperidines
IL58478A0 (en) Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines
JPS54152038A (en) Flameeproof*lowwsmoke hottmelt composition
JPS54107993A (en) Alphaacyanoacrylate composition
GB2034704B (en) 2,6-daiminonebularines
JPS54147931A (en) Antiiulcer composition
GR64915B (en) Improved etomidate-containing compositions
GR64830B (en) Disinfectaut composition
PT69935A (en) Insecticidals compositions
IL56443A0 (en) 2,6-dinitrobenzeneamines
GB2087873B (en) 1,2-dioximes
GB2021108B (en) 6,7 - di - 4 - amino - 2 - quinazolines
PT69225A (en) Compositions
ZA793302B (en) Fasciolicidal compositions
ZA792005B (en) 6,7-benzomorphans
JPS54147934A (en) Antiiangina composition
GB2018769B (en) 2,3-dihydro-4h-1-benzopyran-4-one o-carbamoyl-oximes
PT70100A (en) Farmaceutical compositions
GB2026861B (en) Pharmaceutical compositions containing 5-methyl-7-diethylamino-s-triazolo (1,5- )-pyrimidine
GB2032431B (en) 2,3 - dimethyl - pent - 4en - aldehyde